Skip to main content
Top
Published in: BMC Medical Informatics and Decision Making 1/2014

Open Access 01-12-2014 | Research article

Concordance and predictive value of two adverse drug event data sets

Authors: Aurel Cami, Ben Y Reis

Published in: BMC Medical Informatics and Decision Making | Issue 1/2014

Login to get access

Abstract

Background

Accurate prediction of adverse drug events (ADEs) is an important means of controlling and reducing drug-related morbidity and mortality. Since no single “gold standard” ADE data set exists, a range of different drug safety data sets are currently used for developing ADE prediction models. There is a critical need to assess the degree of concordance between these various ADE data sets and to validate ADE prediction models against multiple reference standards.

Methods

We systematically evaluated the concordance of two widely used ADE data sets – Lexi-comp from 2010 and SIDER from 2012. The strength of the association between ADE (drug) counts in Lexi-comp and SIDER was assessed using Spearman rank correlation, while the differences between the two data sets were characterized in terms of drug categories, ADE categories and ADE frequencies. We also performed a comparative validation of the Predictive Pharmacosafety Networks (PPN) model using both ADE data sets. The predictive power of PPN using each of the two validation sets was assessed using the area under Receiver Operating Characteristic curve (AUROC).

Results

The correlations between the counts of ADEs and drugs in the two data sets were 0.84 (95% CI: 0.82-0.86) and 0.92 (95% CI: 0.91-0.93), respectively. Relative to an earlier snapshot of Lexi-comp from 2005, Lexi-comp 2010 and SIDER 2012 introduced a mean of 1,973 and 4,810 new drug-ADE associations per year, respectively. The difference between these two data sets was most pronounced for Nervous System and Anti-infective drugs, Gastrointestinal and Nervous System ADEs, and postmarketing ADEs. A minor difference of 1.1% was found in the AUROC of PPN when SIDER 2012 was used for validation instead of Lexi-comp 2010.

Conclusions

In conclusion, the ADE and drug counts in Lexi-comp and SIDER data sets were highly correlated and the choice of validation set did not greatly affect the overall prediction performance of PPN. Our results also suggest that it is important to be aware of the differences that exist among ADE data sets, especially in modeling applications focused on specific drug and ADE categories.
Appendix
Available only for authorised users
Literature
1.
go back to reference Johnson JA, Bootman JL: Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med. 1995, 155 (18): 1949-CrossRefPubMed Johnson JA, Bootman JL: Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med. 1995, 155 (18): 1949-CrossRefPubMed
2.
go back to reference Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998, 279 (15): 1200-1205.CrossRefPubMed Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998, 279 (15): 1200-1205.CrossRefPubMed
3.
go back to reference Chiatti C, Bustacchini S, Furneri G, Mantovani L, Cristiani M, Misuraca C, Lattanzio F: The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people. Drug Saf. 2012, 35 (1): 73-87.CrossRefPubMed Chiatti C, Bustacchini S, Furneri G, Mantovani L, Cristiani M, Misuraca C, Lattanzio F: The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people. Drug Saf. 2012, 35 (1): 73-87.CrossRefPubMed
4.
go back to reference Gyllensten H, Jonsson AK, Rehnberg C, Carlsten A: How are the costs of drug-related morbidity measured?: a systematic literature review. Drug Saf. 2012, 35 (3): 207-219.PubMed Gyllensten H, Jonsson AK, Rehnberg C, Carlsten A: How are the costs of drug-related morbidity measured?: a systematic literature review. Drug Saf. 2012, 35 (3): 207-219.PubMed
5.
go back to reference Wu C, Bell CM, Wodchis WP: Incidence and economic burden of adverse drug reactions among elderly patients in Ontario Emergency Departments. Drug Saf. 2012, 35 (9): 769-781.CrossRefPubMedPubMedCentral Wu C, Bell CM, Wodchis WP: Incidence and economic burden of adverse drug reactions among elderly patients in Ontario Emergency Departments. Drug Saf. 2012, 35 (9): 769-781.CrossRefPubMedPubMedCentral
6.
7.
go back to reference Hamon J, Whitebread S, Techer-Etienne V, Le Coq H, Azzaoui K, Urban L: In vitro safety pharmacology profiling: what else beyond hERG?. Future Med Chem. 2009, 1 (4): 645-665.CrossRefPubMed Hamon J, Whitebread S, Techer-Etienne V, Le Coq H, Azzaoui K, Urban L: In vitro safety pharmacology profiling: what else beyond hERG?. Future Med Chem. 2009, 1 (4): 645-665.CrossRefPubMed
8.
go back to reference Fieldent MR, Kolaja KL: The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf. 2008, 7 (2): 107-110.CrossRef Fieldent MR, Kolaja KL: The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf. 2008, 7 (2): 107-110.CrossRef
9.
go back to reference Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R: Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007, 16 (12): 1275-1284.CrossRefPubMed Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R: Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007, 16 (12): 1275-1284.CrossRefPubMed
10.
go back to reference Noren GN, Edwards IR: Modern methods of pharmacovigilance: detecting adverse effects of drugs. Clin Med. 2009, 9 (5): 486-489.CrossRef Noren GN, Edwards IR: Modern methods of pharmacovigilance: detecting adverse effects of drugs. Clin Med. 2009, 9 (5): 486-489.CrossRef
11.
13.
go back to reference Fung M, Thornton A, Mybeck K, Wu JH-h, Hornbuckle K, Muniz E: Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999*. Drug Inf J. 2001, 35 (1): 293-317. Fung M, Thornton A, Mybeck K, Wu JH-h, Hornbuckle K, Muniz E: Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999*. Drug Inf J. 2001, 35 (1): 293-317.
14.
go back to reference MacDonald JS, Robertson RT: Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci. 2009, 110 (1): 40-46.CrossRefPubMed MacDonald JS, Robertson RT: Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci. 2009, 110 (1): 40-46.CrossRefPubMed
15.
go back to reference Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004, 3 (8): 711-716.CrossRefPubMed Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004, 3 (8): 711-716.CrossRefPubMed
16.
go back to reference Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010, 9 (3): 203-214.PubMed Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010, 9 (3): 203-214.PubMed
17.
go back to reference Bai JP, Abernethy DR: Systems pharmacology to predict drug toxicity: integration across levels of biological organization*. Annu Rev Pharmacol Toxicol. 2013, 53: 451-473.CrossRefPubMed Bai JP, Abernethy DR: Systems pharmacology to predict drug toxicity: integration across levels of biological organization*. Annu Rev Pharmacol Toxicol. 2013, 53: 451-473.CrossRefPubMed
18.
go back to reference Hopkins AL: Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008, 4 (11): 682-690.CrossRefPubMed Hopkins AL: Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008, 4 (11): 682-690.CrossRefPubMed
19.
go back to reference Azuaje F: Drug interaction networks: an introduction to translational and clinical applications. Cardiovasc Res. 2013, 97 (4): 631-641.CrossRefPubMed Azuaje F: Drug interaction networks: an introduction to translational and clinical applications. Cardiovasc Res. 2013, 97 (4): 631-641.CrossRefPubMed
20.
go back to reference Atias N, Sharan R: An algorithmic framework for predicting side effects of drugs. J Comput Biol. 2011, 18 (3): 207-218.CrossRefPubMed Atias N, Sharan R: An algorithmic framework for predicting side effects of drugs. J Comput Biol. 2011, 18 (3): 207-218.CrossRefPubMed
21.
go back to reference Cami A, Arnold A, Manzi S, Reis B: Predicting adverse drug events using pharmacological network models. Sci Transl Med. 2011, 3 (114): 114ra127-CrossRefPubMed Cami A, Arnold A, Manzi S, Reis B: Predicting adverse drug events using pharmacological network models. Sci Transl Med. 2011, 3 (114): 114ra127-CrossRefPubMed
23.
go back to reference Liu M, Wu Y, Chen Y, Sun J, Zhao Z, Chen X-w, Matheny ME, Xu H: Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc. 2012, 19 (e1): e28-e35.CrossRefPubMedPubMedCentral Liu M, Wu Y, Chen Y, Sun J, Zhao Z, Chen X-w, Matheny ME, Xu H: Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc. 2012, 19 (e1): e28-e35.CrossRefPubMedPubMedCentral
24.
go back to reference Tatonetti NP, Patrick PY, Daneshjou R, Altman RB: Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012, 4 (125): 125ra131-CrossRef Tatonetti NP, Patrick PY, Daneshjou R, Altman RB: Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012, 4 (125): 125ra131-CrossRef
25.
go back to reference Cheng F, Li W, Wang X, Zhou Y, Wu Z, Shen J, Tang Y: Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013, 53 (4): 744-752.CrossRefPubMed Cheng F, Li W, Wang X, Zhou Y, Wu Z, Shen J, Tang Y: Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013, 53 (4): 744-752.CrossRefPubMed
26.
go back to reference Duran-Frigola M, Aloy P: Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem Biol. 2013, 20 (4): 594-603.CrossRefPubMed Duran-Frigola M, Aloy P: Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem Biol. 2013, 20 (4): 594-603.CrossRefPubMed
27.
go back to reference Lin J, Kuang Q, Li Y, Zhang Y, Sun J, Ding Z, Li M: Prediction of adverse drug reactions by a network based external link prediction method. Anal Methods. 2013, 5 (21): 6120-6127.CrossRef Lin J, Kuang Q, Li Y, Zhang Y, Sun J, Ding Z, Li M: Prediction of adverse drug reactions by a network based external link prediction method. Anal Methods. 2013, 5 (21): 6120-6127.CrossRef
28.
go back to reference Shimazawa R, Ikeda M: Safety information in drug labeling: a comparison of the USA, the UK, and Japan. Pharmacoepidemiol Drug Saf. 2013, 22 (3): 306-318.CrossRefPubMed Shimazawa R, Ikeda M: Safety information in drug labeling: a comparison of the USA, the UK, and Japan. Pharmacoepidemiol Drug Saf. 2013, 22 (3): 306-318.CrossRefPubMed
29.
go back to reference Wang LM, Wong M, Lightwood JM, Cheng CM: Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010, 44 (1): 28-34.CrossRefPubMed Wang LM, Wong M, Lightwood JM, Cheng CM: Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010, 44 (1): 28-34.CrossRefPubMed
30.
go back to reference Duke J, Friedlin J, Li X: Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf. 2013, 22 (3): 294-301.CrossRefPubMed Duke J, Friedlin J, Li X: Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf. 2013, 22 (3): 294-301.CrossRefPubMed
31.
go back to reference Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen D-T, Austin CP: The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011, 3 (80): 80ps16-CrossRefPubMedPubMedCentral Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen D-T, Austin CP: The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011, 3 (80): 80ps16-CrossRefPubMedPubMedCentral
32.
Metadata
Title
Concordance and predictive value of two adverse drug event data sets
Authors
Aurel Cami
Ben Y Reis
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medical Informatics and Decision Making / Issue 1/2014
Electronic ISSN: 1472-6947
DOI
https://doi.org/10.1186/1472-6947-14-74

Other articles of this Issue 1/2014

BMC Medical Informatics and Decision Making 1/2014 Go to the issue